|
|
Novel small-molecule TNF-a modulators as chemoprotective agents
|
5R44CA141749-03
|
$542,156
|
$542,156
|
SHAW, JIAJIU
|
21ST CENTURY THERAPEUTICS, INC.
|
|
|
Targeted Therapy for Non Small Cell Lung Carcinoma: In vivo Feasibility Studies
|
1R43CA162629-01A1
|
$193,879
|
$193,879
|
Serrero, Ginette
|
A AND G PHARMACEUTICAL, INC.
|
|
|
Investigation of a nanoparticle albumin-bound mTOR inhibitor, nab-rapamycin for t
|
1R42CA171552-01
|
$472,301
|
$472,301
|
Desai, Neil
|
AADI, LLC
|
|
|
Breast Cancer Oxaliplatin Microdosing Trial
|
N43CO120084-000
|
$199,969
|
$199,969
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS
|
|
|
Phase 0 Carboplatin Microdosing Diagnostic Trial.
|
N44CO120048-000
|
$1,499,894
|
$1,499,894
|
HENDERSON, PAUL
|
ACCELERATED MEDICAL DIAGNOSTICS
|
|
|
Prevention of Tumor Recurrence Following Surgical Resection (Phase II)
|
6R44CA135967-03
|
$498,107
|
$498,107
|
Wolinsky, Jesse
|
ACUITYBIO CORPORATION
|
|
|
Clinical and Immunologic Evaluation of ProstAtak for Prostate Cancer
|
5R44CA124032-04
|
$1,917,582
|
$1,917,582
|
Aguilar-Cordova, Estuardo
|
ADVANTAGENE, INC
|
|
|
Targeted therapy of pancreatic cancer with in vivo radionuclide generator
|
5R21CA156088-02
|
$216,630
|
$216,630
|
DADACHOVA, EKATERINA
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S4
|
$3,757,417
|
$450,890
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S5
|
$249,999
|
$30,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S6
|
$249,999
|
$30,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Core Support for Cancer Center
|
3P30CA013330-39S7
|
$75,000
|
$9,000
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Proton-coupled folate/antifolate transport
|
5R01CA082621-14
|
$513,291
|
$513,291
|
GOLDMAN, Israel
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Taxol: Mechanisms of Action and Resistance
|
5R01CA077263-12
|
$402,550
|
$402,550
|
HORWITZ, SUSAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Targeting PML for therapy in leukemia-initiating cells
|
4R00CA139009-03
|
$249,000
|
$82,170
|
ITO, KEISUKE
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Development of Novel Drugs to Alleviate CPT-11 Toxicity
|
1R01CA161879-01A1
|
$315,319
|
$315,319
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Chemical Modulation of Orphan Nuclear Receptor Function
|
3R01CA127231-04S1
|
$69,288
|
$69,288
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Chemical Modulation of Orphan Nuclear Receptor Function
|
5R01CA127231-04
|
$267,293
|
$267,293
|
MANI, SRIDHAR
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Inhaled DNA demethylating therapy for lung cancer and bronchial premalignancy
|
5R01CA154755-02
|
$402,645
|
$402,645
|
PEREZ-SOLER, ROMAN
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
EASTERN COOPERATIVE ONCOLOGY GROUP
|
5U10CA014958-38
|
$101,749
|
$101,749
|
Sparano, Joseph
|
ALBERT EINSTEIN COL OF MED YESHIVA UNIV
|
|
|
Expression-Based Multi-Gene Signatures for CRC Recurrence and Chemoselection
|
5R44CA119565-07
|
$999,610
|
$999,610
|
Sears, Christopher
|
AMBERGEN, INC
|
|
|
Community Clinical Oncology Program
|
5U10CA037422-25
|
$4,499,349
|
$1,754,746
|
BRUNER, DEBORAH
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
3U10CA021661-36S1
|
$172,284
|
$134,382
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Radiation Therapy Oncology Group
|
5U10CA021661-36
|
$12,915,055
|
$10,073,743
|
Curran, Walter
|
AMERICAN COLLEGE OF RADIOLOGY
|
|
|
Integrin Targeted Therapy for the Treatment of Ovarian Cancer
|
1R41CA168228-01A1
|
$299,849
|
$299,849
|
Calzone, Frank
|
APPLIED INTEGRIN SCIENCES, INC.
|
|
|
Development of transporter targeted platinum drugs for neuroblastoma
|
1R43CA174132-01
|
$172,738
|
$172,738
|
Mamelok, Richard
|
APRICITY THERAPEUTICS, INC.
|
|
|
Multi-functional Esophaeal Theranostic Delivery System
|
N43CO110053-001
|
$180,000
|
$180,000
|
SHENOY, NARMADA
|
ARAVASC, INC.
|
|
|
A Small Molecule to Activate Cetuximab to Kill K-RAS Mutant Colorectal Tumors
|
1R41CA174031-01
|
$266,641
|
$133,321
|
Jones, Barry
|
ARISAPH PHARMACEUTICALS, INC.
|
|
|
Bay Area Tumor Institute CCOP
|
2U10CA045461-23
|
$486,165
|
$209,051
|
FEUSNER, JAMES
|
BAY AREA TUMOR INSTITUTE
|
|
|
Guideline-based surveillance and treatment of hepatocellular carcinoma
|
5R01CA160738-02
|
$324,738
|
$324,738
|
Davila, Jessica
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
SPORE in Lymphoma
|
2P50CA126752-06
|
$2,300,000
|
$253,000
|
HESLOP, HELEN
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S1
|
$41,433
|
$829
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
3P30CA125123-06S2
|
$75,000
|
$1,500
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Baylor College of Medicine Cancer Center
|
5P30CA125123-06
|
$2,934,758
|
$58,695
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Translational Research in Breast Cancer
|
5P50CA058183-18
|
$2,262,139
|
$1,131,070
|
OSBORNE, C
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
NSABP Participating Sites
|
3U10CA118735-06S1
|
$61,790
|
$22,862
|
Rimawi, Mothaffar
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Therapeutic Targeting of Breast Cancer Tumor Initiating Cells
|
5R01CA148761-03
|
$491,675
|
$162,253
|
Rosen, Jeffrey
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
The Role of SRC-1 in Breast Cancer
|
2R01CA112403-06A1
|
$269,732
|
$89,012
|
XU, JIANMING
|
BAYLOR COLLEGE OF MEDICINE
|
|
|
Chemotherapeutic Agents with Enhanced Selectivity for the Tumor Microenvironment
|
5R01CA140674-03
|
$282,992
|
$282,992
|
PINNEY, KEVIN
|
BAYLOR UNIVERSITY
|
|
|
Virginia Mason Community Clinical Oncology Program
|
5U10CA035192-28
|
$607,994
|
$237,118
|
Nichols, Craig
|
BENAROYA RESEARCH INST AT VIRGINIA MASON
|
|
|
Eastern Cooperative Oncology Group
|
5U10CA080775-14
|
$95,411
|
$95,411
|
BUBLEY, GLENN
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
DF/HCC Kidney Cancer SPORE
|
5P50CA101942-09
|
$2,300,000
|
$276,000
|
McDermott, David
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Optimizing localized therapy for primary liver cancer: a clinical trial and model
|
5K23CA139005-04
|
$169,560
|
$169,560
|
Miksad, Rebecca
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting PML for leukemia therapy.
|
5R01CA142874-03
|
$455,022
|
$227,511
|
PANDOLFI, PIER PAOLO
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Rectifying defects in tumor vasculature to improve chemo- and radiation therapies
|
5R01CA129339-05
|
$342,168
|
$342,168
|
SENGER, DONALD
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
Targeting prostate cancer stem cells to delay prostate cancer progression
|
5R21CA153355-02
|
$227,070
|
$227,070
|
ZHOU, JIN-RONG
|
BETH ISRAEL DEACONESS MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S1
|
$300,000
|
$108,000
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
3U10CA139519-03S2
|
$139,989
|
$50,396
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
The MB-CCOP at Boston Medical Center
|
5U10CA139519-03
|
$310,336
|
$111,721
|
Kachnic, Lisa
|
BOSTON MEDICAL CENTER
|
|
|
Boston University Cross-Disciplinary Training in Nanotechnology for Cancer
|
3R25CA153955-03S1
|
$45,144
|
$11,286
|
GOLDBERG, BENNETT
|
BOSTON UNIVERSITY
|
|
Total relevant funding to Chemotherapy for this search: $519,626,105
|
